Source: International Congress 2019 – Identification of new targets and therapeutic strategies for lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Mcconnell (Belfast, United Kingdom), G. Thillaiyampalam (Brisbane, Australia), A. Elbanna (Belfast, United Kingdom), A. Brown (Belfast, United Kingdom), M. Ennis (Belfast, United Kingdom), S. Zhang (Londonderry, United Kingdom), M. Shields (Belfast, United Kingdom), B. Schock (Belfast, United Kingdom). Pharmacological induction of A20: Anti-inflammatory effects in paediatric asthma. 2357

Member's Comments

No comment yet.

Related content which might interest you: An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in the mouse Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 The anti-inflammatory effects of sulforaphane are not mediated by the Nrf2 pathway Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases Year: 2014 Anti-inflammatory effects of aerobic exercise in a murine model of asthma: Role of leukotrienes pathway Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Differential effects of simvastatin and dexamethasone on TLR3-induced anti-viral cytokines in asthmatic epithelium Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Synergistic effects of p38 MAPK inhibition with a corticosteroid in alveolar macrophages from corticosteroid insensitive asthma patients Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD Year: 2013 Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Enhanced anti-inflammatory gene expression in humans following inhaled budesonide Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013 A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4 Source: International Congress 2014 – Animal models in respiratory drug development Year: 2014 Update on anti-inflammatory therapy in asthma Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease Year: 2012 RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Neutraligands of CXCL12: Anti-inflammatory activity in an allergic model of asthma Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011 Rapamycin protects OVA induced asthma in mice through regulating autophagy Source: International Congress 2015 – Exploring mechanisms in obstructive airway diseases Year: 2015 Resveratrol upregalates PTEN and inhibits MUC5AC expression in ovalbumin (OVA)-induced asthma model mice Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action Year: 2016 Anti-inflammatory effect of low dose theophylline in school children with bronchial asthma Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 AZD5069: Pharmacological profile of a CXCR2 antagonist in development for the treatment of respiratory disorders Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 The in vitro profile of ADC3680, a potent and selective CRTh2 antagonist for the treatment of inadequately controlled asthma Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics Source: International Congress 2014 – Asthma and COPD management Year: 2014 Novel, highly potent and selective JAK3 inhibitor disrupting IL-4/IL-13 signaling in asthma therapy Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015 Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014 Aerobic training reverses the inhibition in the expression of glucocorticoid receptors and decreases the Th2 allergic inflammation in asthma model Source: Annual Congress 2013 –The multiple faces of stress in lung injury Year: 2013